A new study shows that one quarter of people undergoing surgery for stomach cancer have the recommended number of lymph nodes removed, that this number varies widely by geographic region, and that adequate lymph node removal is related to people surviving this cancer.
Results of the MRC Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial show that perioperative chemotherapy (the use of chemotherapy before and after surgery) improved overall survival and delayed cancer growth for people with operable cancer of the stomach and lower esophagus.